GVK Biosciences, a leading research and development organisation, has unveiled a new brand CLINOGENT in the clinical development industry to provide an end-to-end clinical development services from offering bioequivalence studies for generic pharma and late phase patient based clinical studies for research-based companies.
Speaking at a press conference, Manni Kantipudi. chief executive officer, says, “CLINOGENT will be unique clinical service provider in India, as it will be able to address the clinical needs of both Innovator bio-pharmaceutical and generic companies world-wide. Our vision is to become the Asia's leading clinical development provider by 2020.”
CLINOGENT is uniquely positioned as a comprehensive full service clinical development solutions organisation that will cater to end-to-end research and development solutions to the pharmaceutical, generics, biotechnology companies, and academic institutions across the globe with the focus markets being USA, Europe and Asia. The launch of a new brand is a part of GVK BIO’s growth plan in taking the organisation to the next level and creating a benchmark in the industry.
It is expected to bring exceptional expertise in delivering solutions to complex data analysis and medical communication problems to customer’s the world over. This will endeavor to provide innovative solutions to all the clinical and scientific challenges that their customers face in the business.
CLINOGENT is a constructed word that implies “Innovative and Intelligent Clinical development solutions Organisation. The alphabet ‘i’ is a specially created unit having a Red and Orange colour combination that represents Warmth, Power, Energy and emotes one to take an action. The dot of ‘i’signifies life, pioneering spirit, leadership qualities, promoting ambition and determination.
“The clinical development is expected to reach $23 billion by 2016 and it is set to to grow at an average annual rate of 10.5 per cent”, said Dr Chetan Prabhakar, senior vice president, GVK biosciences.
He said that the recent mergers and acquisitions within pharma and generics space only mean that these companies would focus on their core competence and outsource large segments of their R&D process to bring in much needed efficiencies–of scale, time and costs, thus giving rise for a need of a full-service clinical development solutions provider.
CLINOGENT is uniquely positioned as a comprehensive full service clinical development solutions organisation that will cater to end-to-end research and development solutions to the pharmaceutical, generics, biotechnology companies, and academic institutions across the globe with the focus markets being USA, Europe and Asia. The launch of a new brand is a part of GVK BIO’s growth plan in taking the organisation to the next level and creating a benchmark in the industry
He said that the industry needed a better clarity in the existing regulatory norms and hoped that the new government will work through all the issues in the clinical trials industry. The company is expected to complete the acquisition Inogent laboratories this year as part of its growth story.